American Journal of Kidney Diseases
Volume 56, Issue 1 , Pages 10-13 , July 2010

Donor Pretreatment With Dopamine and Graft Function Following Kidney Transplant: A Strategy to Improve Transplant Outcomes?

  • John S. Gill, MD, MS

      Affiliations

    • Corresponding Author InformationAddress correspondence to John S. Gill, MD, MS, Providence Bldg, St Paul's Hospital, Ward 6a, 1081 Burrard St, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • William Gourlay, MD
    • ,
  • Jagbir Gill, MD, SM

References 

  1. United Network Of Organ Sharing. http://www.unos.orgAccessed November 13, 2009
  2. Leichtman AB, Cohen D, Keith D, et al. Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant. 2008;8(4 pt 2):946–957
  3. Tuttle-Newhall JE, Krishnan SM, Levy MF, McBride V, Orlowski JP, Sung RS. Organ donation and utilization in the United States: 1998-2007. Am J Transplant. 2009;9(4 pt 2):879–893
  4. Abecassis MM, Burke R, Klintmalm GB, et al. American Society of Transplant Surgeons transplant center outcomes requirements—a threat to innovation. Am J Transplant. 2009;9(6):1279–1286
  5. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003;75(4):482–487
  6. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302(10):1067–1075
  7. Dunning J, Khasati N, Barnard J. Low dose (renal dose) dopamine in the critically ill patient. Interact Cardiovasc Thorac Surg. 2004;3(1):114–117
  8. Chok MK, Ferlicot S, Conti M, et al. Renoprotective potency of heme oxygenase-1 induction in rat renal ischemia-reperfusion. Inflamm Allergy Drug Targets. 2009;8(4):252–259
  9. Katori M, Buelow R, Ke B, et al. Heme oxygenase-1 overexpression protects rat hearts from cold ischemia/reperfusion injury via an antiapoptotic pathway. Transplantation. 2002;73(2):287–292
  10. Schnuelle P, Yard BA, Braun C, et al. Impact of donor dopamine on immediate graft function after kidney transplantation. Am J Transplant. 2004;4(3):419–426
  11. Schnuelle P, Lorenz D, Mueller A, Trede M, Van Der Woude FJ. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int. 1999;56(2):738–746
  12. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation. 2001;72(3):455–463
  13. Pérez López S, Otero Hernández J, Vázquez Moreno N, et al. Brain death effects on catecholamine levels and subsequent cardiac damage assessed in organ donors. J Heart Lung Transplant. 2009;28(8):815–820
  14. Spicer ST, Gruenewald S, O'Connell PJ, Chapman JR, Nankivell BJ. Low-dose dopamine after kidney transplantation: assessment by Doppler ultrasound. Clin Transplant. 1999;13(6):479–483
  15. Dalton RS, Webber JN, Cameron C, et al. Physiologic impact of low-dose dopamine on renal function in the early post renal transplant period. Transplantation. 2005;79(11):1561–1567
  16. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009;360(1):7–19
  17. Shilliday IR, Sherif M. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients. Cochrane Database Syst Rev. 2007;17(4):CD003421

 Originally published online as doi:10.1053/j.ajkd.2010.01.007 on March 18, 2010.

PII: S0272-6386(10)00037-5

doi: 10.1053/j.ajkd.2010.01.007

American Journal of Kidney Diseases
Volume 56, Issue 1 , Pages 10-13 , July 2010

Article Tools